Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Assets (2016 - 2025)

Historic Assets for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $18.4 million.

  • RedHill Biopharma's Assets fell 1656.83% to $18.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.4 million, marking a year-over-year decrease of 1656.83%. This contributed to the annual value of $18.0 million for FY2024, which is 2171.22% down from last year.
  • Per RedHill Biopharma's latest filing, its Assets stood at $18.4 million for Q2 2025, which was down 1656.83% from $18.0 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Assets high stood at $220.1 million for Q1 2021, and its period low was $18.0 million during Q4 2024.
  • For the 5-year period, RedHill Biopharma's Assets averaged around $115.6 million, with its median value being $158.0 million (2022).
  • In the last 5 years, RedHill Biopharma's Assets surged by 5341.72% in 2021 and then plummeted by 8549.32% in 2023.
  • RedHill Biopharma's Assets (Quarter) stood at $181.2 million in 2021, then fell by 12.32% to $158.9 million in 2022, then crashed by 85.49% to $23.0 million in 2023, then fell by 21.71% to $18.0 million in 2024, then increased by 1.84% to $18.4 million in 2025.
  • Its Assets stands at $18.4 million for Q2 2025, versus $18.0 million for Q4 2024 and $22.0 million for Q2 2024.